New cheaper version of melanoma drug enters testing
NCT ID NCT07476326
Summary
This study aims to see if a new, potentially more affordable version of the cancer drug Opdivo (called Bmab1700) behaves similarly in the body. It will involve 120 adults whose melanoma has been completely removed by surgery. Participants will receive either the new drug or Opdivo to compare drug levels, safety, and how the immune system responds.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.